94. Primary sclerosing cholangitis Clinical trials / Disease details


Clinical trials : 142 Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03678480
(ClinicalTrials.gov)
March 1, 202118/9/2018A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis;Cholangitis;Cholangitis, Sclerosing;Bile Duct Diseases;Biliary Tract Diseases;Digestive System Diseases;AdolescentDrug: HTD1801;Drug: Ursodeoxycholic AcidHighTide Biopharma Pty LtdNULLWithdrawn12 Years17 YearsAll0Phase 2NULL
2NCT03333928
(ClinicalTrials.gov)
February 9, 201827/10/2017A POC and Dose-Ranging Study of HTD1801 in PSC PatientsA Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC)Drug: HTD1801;Drug: PlaceboHighTide Biopharma Pty LtdNULLCompleted18 Years75 YearsAll59Phase 2United States;Canada
3NCT03099603
(ClinicalTrials.gov)
March 24, 201714/3/2017A Study of HTD1801 in Healthy SubjectsA First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy SubjectsPrimary Sclerosing CholangitisDrug: HTD1801HighTide Biopharma Pty LtdNULLCompleted18 Years50 YearsAll32Phase 1Australia